Cargando…
Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the leading cause of cancer-related mortality worldwide. It is responsible for 80–85% of lung cancer cases. NSCLC can be divided into several groups, led by adenocarcinoma (ADC)–40–50% and squamous cell carcinoma (SCC)–20–...
Autores principales: | Rekowska, Anna, Rola, Piotr, Wójcik-Superczyńska, Magdalena, Chmielewska, Izabela, Krawczyk, Paweł, Milanowski, Janusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140000/ https://www.ncbi.nlm.nih.gov/pubmed/35621675 http://dx.doi.org/10.3390/curroncol29050285 |
Ejemplares similares
-
Breaking the ‘Undruggable’ Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with KRAS Mutations—A Comprehensive Review and Description of Single Site Experience
por: Chmielewska, Izabela, et al.
Publicado: (2023) -
In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation
por: Wieleba, Irena, et al.
Publicado: (2022) -
The efficacy of T790M mutation testing in liquid biopsy—Real clinic data
por: Krawczyk, Paweł, et al.
Publicado: (2022) -
Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
por: Nicoś, Marcin, et al.
Publicado: (2019) -
Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)